APRE/ 05/07/2026 · 11:15 AM Why Oppenheimer is Bullish on Tiny Biotech Aprea Therapeutics Oppenheimer backs Aprea with $5 target. Its cancer drug shows early promise, and low valuation offers big upside potential.
